Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
DLL3 – A Breakthrough Target for Small Cell Lung Cancer Therapy-DIMA ...
中国生物制药与勃林格殷格翰达成肿瘤创新产品合作，这几款产品到底成色如何？_财富号_东方财富网
重磅 | 勃林格殷格翰小细胞肺癌新药DLL3/CD3双抗BI 764532临床试验在华获批！ | Boehringer Ingelheim CN
Zongertinib （BI 764532） | pHER2&EGF抑制剂 | 抗肿瘤 | TargetMol
Bi 764532 – Application in Therapy and Current Clinical Research
Study on BI 764532 for Patients with Relapsed or Refractory Small Cell ...
Full article: Phase I trial of the DLL3/CD3 bispecific T-cell engager ...
BI 764532 / Boehringer Ingelheim, Oxford BioTherap
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG ...
勃林格殷格翰DLL3/CD3双抗BI 764532在国内获批临床，治疗小细胞肺癌 - 知乎
勃林格殷格翰DLL3/CD3双抗BI 764532在国内获批临床
BI 764532 for Small Cell Lung Cancer Clinical Trial 2024 | Power
研究报告 | 靶向DLL3药物在研现状_细胞
BI 764532 Earns FDA FTD in Large Cell Lung Neuroendocrine Carcinoma
海外医疗前沿：小细胞肺癌新药BI 764532获美国FDA快速通道认证-海外医疗视频-盛诺一家
Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily ...
BI 764532 Earns FDA FTD in SCLC and Extrapulmonary Neuroendocrine Carcinoma
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in ...
BI 764532 Shows Early Efficacy, Manageable Tolerability in DLL3+ SCLC ...
BI 764532 Bispecific Antibody for DLL3 Small Cell Lung Cancer
Fast track-status voor BI 764532 bij SCLC en extrapulmonale neuro ...
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients ...
Obrixtamig (BI 764532) | Anti-CD3E/DLL3 Antibody | MedChemExpress
BI 764532: a novel T-cell engager for patients with DLL3+ SCLC and NEC ...
前沿靶向药BI 764532：晚期小细胞肺癌的新希望！ - MedFind
BI 764532 Show Promising Early Results in DLL3+ SCLC and Neuroendocrine ...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received ...
DAREON-5 (1438-0005) | InOncology – Boehringer Ingelheim
FDA Grants FTD to BI 764532 in DLL3+ SCLC and Neuroendocrine Carcinoma
Pharma Jonpi . / 1.1 / .: SMALL_CELL_LUNG_CANCER SEGUNDA LÍNEA ...
靶向药Obrixtamig (BI 764532)最新临床研究：为小细胞肺癌、神经内分泌肿瘤患者带来新希望 - MedFind
Obrixtamig (BI 764532) | 抗CD3E/DLL3抗体 | MCE
1731TiP Obrixtamig (BI 764532) in patients (pts) with relapsed ...
First-in-human dose-escalation trial of BI 764532, a delta-like ligand ...
WATCH>>> Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and ...
Dareon-5 Trial Study of BI 764532 | Boehringer Ingelheim
FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC ...
Phase I trial of BI 764532, a T-cell engager for DLL3-positive NEC and ...
PHARMA JONPI .: SMALL_CELL_LUNG_CANCER SEGUNDA LÍNEA . BOEHRINGER : SU ...
小细胞肺癌前沿“双抗”药BI 764532，让近4成小细胞肺癌和神经内分泌癌的患者肿瘤得到控制!-出国看病-盛诺一家
A study to test different doses of BI 764532 in patients with small ...
Refining first-line regimens for extensive-stage small-cell lung cancer ...
Dareon-5 Trial Study of BI 764532 | Boehringer Ingelheim | Boehringer ...
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help ...
Dareon-5 Trial Study of BI 764532 | Boehringer Ingelheim USA
2023年ASCO几个值得关注的研究(上)|ASCO|内分泌癌|细胞|肺癌|肿瘤|-健康界
研究报告 | 靶向DLL3药物在研现状 DLL3靶点介绍DLL3是一种高度肿瘤选择性的细胞表面靶点，主要表达于神经或者神经内分泌肿瘤，包括小 ...
.jpg)
